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Abstract
Currently, 17 million people worldwide are receiving antiretroviral therapy (ART) for 
human immunodeficiency viral (HIV) infection. There has been a dramatic decline in 
mortality from HIV infection in the last decade due to increased availability of ART. HIV-
associated cardiac failure is on the increase, with more cases of diastolic dysfunction 
reported in the ART era. HIV increases the risk of CVD, because of longer survival on 
ART, ongoing subclinical inflammation, traditional cardiovascular risk factors and the 
complications of chronic ART use. HIV-associated CVD encompasses a wide spectrum 
of heterogeneous clinical entities, which include diastolic dysfunction, asymptomatic left 
ventricular dysfunction, cardiomyopathy, myocarditis, heart failure, myocardial fibro-
sis, myocardial steatosis, pulmonary hypertension, peripheral arterial disease, cerebro-
vascular disease, infective endocarditis, coronary artery disease and cardiac neoplasms 
(e.g. Kaposi sarcoma and B-cell immunoblastic lymphoma). In this chapter, we review 
the complex association of HIV infection and CVD. We describe important recent devel-
opments and perspectives based on a systematic analysis of the important advances in 
this field published in the last decade.
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1. Introduction
By end of 2017, about 37 million people worldwide were living with the human immunodefi-
ciency virus (HIV) [1]. Sub-Saharan Africa (SSA) is the region of the world most severely affected 
by HIV infection, where 69% of the global population of people living with HIV reside [2]. South 
Africa has the largest population of HIV infected persons: an adult prevalence of 18.9% and an 
estimated 7.1 million people living with HIV in 2016 [2]. At the end of 2016, the country had 
270,000 new infections while 110,000 South Africans died from AIDS-related illnesses [3].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The connection between HIV infection and cardiovascular disease (CVD) was established 
quite early in the history of the AIDS pandemic [4]. Early studies in Africans with HIV infection 
reported that CVD, involving predominantly the myocardium and pericardium, occurred in 
up to 60% of patients studied [5]. The frequency and pattern of CVD in HIV infected persons 
is determined by geography, access to combination antiretroviral therapy (ART) and degree 
of immunosuppression [6]; and several studies have reported the incidence of HIV-associated 
CVD to be much higher in SSA compared to high-income countries [7, 8].
The risk of CVD in HIV infected individuals is influenced not only by traditional cardiovascu-
lar risk factors, genetics and family history, but also by the effect of ART and the effect of HIV 
itself [9]. Common HIV-associated CVD manifestations include HIV-associated cardiomyop-
athy (38%), pericardial disease (13%) and pulmonary hypertension (8%) [10]. Approximately 
50% of asymptomatic HIV infected persons without known CVD have been found to have 
diastolic dysfunction on echocardiography [11]. Studies from Africa have found the preva-
lence of diastolic dysfunction in HIV infected patients to be much higher and to be more 
severe in patients with AIDS at autopsy, where up to 40% of HIV infected patients were found 
to have histological evidence of interstitial fibrosis [12]. Despite effective suppression of viral 
replication, treated HIV infection is associated with persistent inflammation, tissue fibrosis, 
suboptimal immune recovery and organ damage [13].
2. Heart failure
Heart failure, a regular consequence of cardiac disease, appears to be more common among 
HIV patients. The global prevalence of heart failure in HIV infected patients in the pre-ART 
era was between 4 and 5 million cases [13]. Heart failure remains a significant problem in HIV 
infected patients; the incidence of HIV/AIDS related heart failure is on increase, and current 
evidence suggests that diastolic, rather than systolic dysfunction is the predominant form of 
heart failure in the era of ART [14, 15]. Risk factors for systolic dysfunction included elevated 
high-sensitivity C-reactive protein, tobacco use and prior myocardial infarction (MI); for dia-
stolic dysfunction, risk factors were hypertension and older age [16–18]. In 2242 HIV infected 
patients on ART from 11 contemporaneous studies, systolic and diastolic dysfunction were in 
8.3% and 43.4% of study subject, respectively [16].
2.1. Pathogenesis of HIV-associated heart failure
Several mechanisms may be responsible HIV-associated heart failure, as shown in Figure 1, 
including direct HIV infection, toxicity of HIV components and ART, opportunistic infections 
and abnormal autoimmune responses to viral infection [19, 20]. HIV associated myocarditis, 
malignancy, myocardial fibrosis, myocardial steatosis, arterial stiffness, endothelial dysfunc-
tion capillary leak syndrome and abnormal coagulation have been considered in the patho-
genesis [21–27]. Also, traditional risk factors such as hypertension, diabetes, dyslipidaemia 
and smoking are more common in HIV infected people [28].
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2.2. Myocarditis in HIV
At autopsy, myocarditis was reported in up to 50% of AIDS patients who had not died from 
cardiac reasons [29]. Direct invasion of cardiomyocytes by HIV has been described, however, 
the virus affects the myocardial cells in a haphazard fashion with no clear association between 
viral load and extent of myocardial involvement [30]. The invasion of cardiomyocytes in 
HIV infection can be through other microorganisms, including fungi (Candida, Histoplasma 
capsulatum [31], Cryptococcus neoformans [32], Aspergillus [32]); viruses (Herpes simplex [33], 
cytomegalovirus [30], Coxsackievirus B3 [34], Parvovirus [33]); bacteria (Mycobacterium 
 tuberculosis [35], Mycobacterium avium [36]) and parasites (Toxoplasma gondii [37]).
Myocarditis with lymphocytic infiltration was reported in 40–52% of patients who died of 
AIDS in the pre-ART era, although no specific pathogen was reported in most affected patients 
and clinical presentation was heterogeneous with most remaining asymptomatic despite 
ongoing subclinical myocardial oedema and inflammation (Figure 2) [30]. In different study 
of HIV-associated cardiomyopathy, endomyocardial biopsy (EMB) of almost cases revealed 
myocarditis with cardiotropic viral infections [38]. The prevalence of myocarditis and cardio-
tropic viral genomes in HIV-associated cardiomyopathy, HIV uninfected idiopathic dilated 
cardiomyopathy (DCM) patients and orthotopic heart transplant recipients was compared 
using EMB and the immunohistological criteria of the World Heart Federation in 33 patients. 
Myocarditis was present in 44% of HIV-associated cardiomyopathy, 36% of heart transplant 
recipients and 25% of participants with idiopathic DCM. Multiple viruses were identified in 
most cases. Cardiotropic viral infection was present in all HIV-associated cardiomyopathy 
patients, with HIV-associated cardiomyopathy, heart transplant recipients and idiopathic 
DCM patients having an average of 2.5, 2.2 and 1.1 viruses per individual, respectively [39].
Viral and opportunistic infections trigger myocarditis in the setting of uncontrolled HIV 
infection. Direct invasion of cardiac myocytes by cardiotropic viruses, including HIV, leads to 
a local cytokine release and subsequent infiltration of the myocardium with clonal expansion 




of B cells [40]. Reduction in opportunistic infections in patients on ART may be responsible 
for the impressive drop in myocarditis rates and declining prevalence of HIV-associated car-
diomyopathy [15, 41, 42].
2.3. Cardiomyopathy and systolic dysfunction in HIV
The most commonly reported cardiac manifestations of HIV/AIDS in SSA are cardiomyopa-
thy, pericardial disease (related to tuberculosis), and pulmonary hypertension [10]. Initial 
descriptions of HIV-associated cardiomyopathy have evolved since the 1980s [43]. The patho-
genesis of HIV-associated cardiomyopathy is multifactorial and can be direct action of HIV 
on myocardial tissue or from proteolytic enzymes and cytokine mediators induced by HIV 
alone or in conjunction with cardiotropic viruses [44]. There has been a marked reduction in 
incidence of HIV-associated cardiomyopathy after the introduction of ART [15, 26, 41].
HIV-associated cardiomyopathy was showed manifestations of systolic dysfunction associ-
ated with a dilated left ventricle and indicated a poor prognosis [4]. The clinical presentation 
of HIV-associated cardiomyopathy is similar to that of DCM in HIV uninfected persons, and 
pathological features include dilated cardiac chambers with endocardial fibrosis and mural 
thrombus (Figure 3) [45]. Histologically, it manifests as myocyte hypertrophy and degenera-
tion with increased interstitial and endocardial fibrin collagen and evidence of prior myocar-
ditis [45]. However, more recent reports indicate that HIV-associated cardiomyopathy more 
commonly manifests with subclinical diastolic dysfunction, particularly in individuals with 
well controlled HIV infection [46]. Contemporaneous series of significant systolic dysfunction 
in treated HIV infection have been associated with prior myocardial infarction [47].
Figure 2. CMR T2-weighted short-tau inversion recovery image showing elevated myocardial: Skeletal muscle signal 
intensity ratio of the lateral wall (white arrows) in a patient with HIV-associated acute myocarditis. Regions of interest 
drawn in blue.
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A phenotype of HIV-associated heart muscle disease with normal chamber size and mildly 
impaired systolic function increases risk of heart failure, even in the absence of coronary 
artery disease [48].
2.4. Diastolic dysfunction in HIV
Left ventricular dysfunction associated with HIV is often clinically silent but may progress to 
symptomatic heart failure. Many studies have reported high incidence of diastolic dysfunc-
tion in HIV (Figure 4) [11, 12, 16–18, 22, 23, 47, 49, 50]. In addition, diastolic dysfunction 
is considered an early marker of coronary artery disease in HIV uninfected patients with-
out cardiac symptoms and preserved systolic function [51]. Diastolic dysfunction in HIV is 
associated with longer duration of HIV infection, higher body mass index and exposure to 
zidovudine [52, 53]. In different echocardiographic screening studies of asymptomatic HIV 
infected individuals, diastolic dysfunction was seen in 26–48% [46, 47, 49, 54]. In these studies, 
diastolic dysfunction has been associated with elevated body mass, total cholesterol, hyper-
tension, smoking and viral load.
Figure 3. CMR balanced steady state free precession images showing (A) 4-chamber view, (B) 2-chamber view, and (C) 
a mid-ventricular short-axis image; and (D) late gadolinium enhancement image showing linear mid-wall enhancement 




3. Myocardial fibrosis in HIV
Myocardial fibrosis an important reason of development and progression systolic and dia-
stolic cardiac failure [55]. There is histological evidence of interstitial fibrosis at autopsy in 
40% of subjects with HIV infection [29]. CMR studies have demonstrated a prevalence of focal 
fibrosis in asymptomatic HIV infected individuals of close to 80% (Figure 5) [22, 23, 25, 56]. 
Diffuse myocardial fibrosis estimated by extracellular volume (ECV) calculation was also 
found to be elevated in HIV infected individuals [56].
Figure 5. Late post gadolinium images showing mid-wall focal fibrosis in the basal inferolateral wall in (a) 3-chamber 
view and in the lateral wall in (B) short-axis (white arrows depict the fibrosis).
Figure 4. CMR cine tagging using spatial modulation of magnetisation in a short axis image through the mid left 
ventricle at end-diastole (a) and at end-systole (B) in a patient infected with HIV. Tagging for strain and strain rate 
imaging in circumferential, longitudinal and radial directions is one of the main techniques for assessment of diastolic 
dysfunction with CMR.
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4. Myocardial steatosis in HIV
Cardiovascular magnetic resonance spectroscopy studies have reported increased incidence 
of myocardial lipidosis in HIV infected patients receiving ART, even in the absence of cardio-
vascular symptoms [22, 25]. In these studies, steatosis was associated with elevated serum 
lipid levels, duration of ART use and impaired strain.
5. HIV-associated pulmonary arterial hypertension
Primary pulmonary arterial hypertension is rare in HIV infected persons, with a prevalence of 
0.5% [57]. The use of ART has not impacted on the epidemiology of HIV-associated pulmonary 
arterial hypertension [58]. There is no correlation between HIV-associated pulmonary arte-
rial hypertension and CD4 cell count, HIV viremia, or duration since HIV diagnosis [47]. The 
pathogenesis of HIV-associated pulmonary arterial hypertension is poorly understood, with 
inflammatory and genetic factors both implicated [59]. Pulmonary hypertension in HIV occurs 
without documented thromboembolic disease, intravenous drug use or pulmonary infections 
[57, 58]. In a study of 47 patients in the Swiss Cohort Study, patients receiving ART had a 
significantly decreased median right ventricular systolic pressure over right atrial pressure 
gradient compared to patients who did not receive ART [60]. ART has also been reported to 
improve the 6 minute walk test in HIV infected patients with pulmonary hypertension, but 
with no effect on haemodynamic parameters [61]. Histologically, HIV-associated pulmonary 
arterial hypertension manifests most commonly as a plexogenic pulmonary arteriopathy, but 
thrombotic pulmonary arteriopathy and pulmonary veno-occlusive disease also described [62].
6. Pericardial disease in HIV
Pericardial effusion and pericarditis are encountered frequently in patients with HIV infec-
tion. The prevalence of symptomatic pericardial effusions before the advent of ART was up 
to 11% of patients with AIDS [63]. However, in the ART era, the incidence of pericardial effu-
sions in HIV is much less: in a multicentre cohort study of treated HIV patients, only 2 of 872 
HIV infected patients had pericardial effusions, neither clinically important [64]. Using CMR 
with greater resolution, our group has demonstrated the prevalence of small, asymptomatic 
pericardial effusions to be much higher [23]. While generally nonspecific, pericardial effu-
sions may indicate active inflammation and may be associated with subclinical myocarditis 
or disseminated tuberculosis, particularly in patients with low CD4 cell counts. In patients 
with large pericardial effusions, Mycobacterium tuberculosis is likely pathogen, especially in 
tuberculosis endemic regions [65]. In prospective study of patients with a large pericardial 
effusion, tuberculosis was identified as cause in 85% of cases [66]. In HIV, tuberculous pericar-
ditis is commonly associated with heart failure [67]. HIV is associated with reduced incidence 




Mortality of pericardial effusions in HIV-infected patients is based on the severity and aeti-
ology of the disease, especially if associated with tuberculosis [69]. We have demonstrated 
more frequent myocardial fibrosis in HIV-associated pericardial constriction when compared 
to those without HIV infection [35]. Prednisone does not reduce mortality in tuberculous 
pericarditis, but has been shown to be associated with reduced hospitalisation and constric-
tion, but with increased risk of malignancies in those with HIV infection [70]. Other causes of 
pericarditis and pericardial effusions in HIV include HIV itself, bacterial infections, Kaposi’s 
sarcoma and lymphoma [71, 72].
7. Infective endocarditis in HIV
The epidemiology and clinical profile of infective endocarditis in HIV infection are the same as 
in uninfected individuals [73]. The one setting where HIV is associated with increased risk of 
infective endocarditis is intravenous drug abuse. Staphylococcus aureus, Streptococcus  viridans 
and Salmonella species are the most common organisms and the tricuspid valve is most 
involved in intravenous drug users developing infective endocarditis [74, 75]. Nonbacterial 
(marantic) endocarditis has been described in HIV, usually clinically silent and manifests 
with large, friable, sterile vegetations on the cardiac valves, which can lead to pulmonary 
embolization [75]. Patients with low CD4 counts have a poorer prognosis when they develop 
infective endocarditis [76]. Rates of infective endocarditis have decreased with the advent of 
ARV therapy [76]. When intravenous drug use is excluded, HIV infection has not been shown 
to be a risk factor for infective endocarditis [77].
8. Coronary artery disease in HIV
HIV-infected patients are known to be at risk for premature coronary artery disease (CAD) 
[78]. Different factors related to HIV can lead to development atherosclerosis, including 
immune dysfunction, proliferation of T-cells, inflammation, endothelial dysfunction, and 
lipid abnormalities [79, 80]. During atherogenesis, HIV promotes monocyte penetration 
of the vascular intima to promote secretion of cytokines and expression of endothelial cell 
adhesion molecules [81]. The process of endothelial dysfunction in HIV patients may be 
driven by HIV transcription factors [82]. Increased risk of CVD in HIV infected patients is 
directly related to lower CD4 T-cell counts [83]. Higher number of activated CD8 T-cells 
is observed in relation to increased rates of coronary artery plaque and carotid artery 
 stiffness [84].
In the early stage of HIV infection both total cholesterol and high-density lipoprotein choles-
terol are decreased [85]. Lower levels of apolipoprotein B and smaller low-density lipoprotein 
cholesterol have been reported in more advanced stages of HIV infection [86]. In addition, 
deleterious metabolic effects such as dyslipidaemia and insulin resistance after exposure to 
certain ART treatments have been reported [79]. Recent studies observed that HIV infected 
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patients presented with large thrombus burden than atherosclerotic plaques suggesting 
de novo arteriothrombosis and thrombophilia as possible causes of CAD events [87, 88].
9. Cardiovascular malignancy in HIV
Cardiac malignancy usually manifests late in HIV disease. Kaposi’s sarcoma and cardiac 
lymphoma are the main malignancies associated with HIV [89]. Non-Hodgkin lymphoma 
occurs 25–60 times more in HIV infected patients [90]. Cardiac lymphoma can infiltrate the 
myocardium, the subendocardial layer or be located within pericardial effusion [90]. Clinical 
features include dyspnoea, right-sided heart failure, heart failure, chest pain and arrhythmia. 
Presentations range from asymptomatic to cardiac tamponade, myocardial infarction, heart 
failure or conduction abnormalities [91].
In the pre-ART era, the prevalence of Kaposi’s sarcoma from autopsy studies ranged from 
12 to 28%, however, cardiac sarcomas were rare [6, 62]. In Kaposi’s sarcoma, the coronary 
arteries are not affected. The incidence of non-Hodgkin lymphoma is not related to the level 
of immunosuppression and has not changed with ART use [92].
10. Conclusion
Two third of those infected with HIV reside in SSA. Currently, 17 million people globally 
receive ART for HIV infection. This widespread use of ART has been associated with a dra-
matic reduction in HIV-related mortality. CVD and heart failure are on the increase in HIV: 
the mechanisms responsible for HIV-associated CVD are manifold and incompletely under-
stood. Diastolic dysfunction has emerged as the dominant form of HIV-associated CVD in the 
era of ART. HIV-associated CVD encompasses heterogeneous disorders and has the propen-
sity to involve every segment of the cardiovascular axis. We have described important recent 
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